A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer

Journal of Biological Chemistry

Volumn 289, Issue 8, 2014, Pages 5208-5216

  Hoffmann, Gesine ^a,d   Breitenbücher, Frank ^b   Schuler, Martin ^b,c   Ehrenhofer Murray, Ann E ^b,d  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLATION; CELL DEATH;

CANCER CELLS; CANCER THERAPY; DEACETYLASE; DEACETYLATION; NON SMALL CELL LUNG CANCER; PHARMACOLOGICAL INHIBITION; SMALL MOLECULES; TARGET GENES;

DISEASES;

AEM 1; AEM 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ENZYME INHIBITOR; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CDKN1A GENE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DEACETYLATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; IC 50; LUNG NON SMALL CELL CANCER; NONHUMAN; NOXA GENE; PRIORITY JOURNAL; PUMA GENE; SACCHAROMYCES CEREVISIAE;

CANCER BIOLOGY; HISTONE DEACETYLASE INHIBITORS; P53; SIRT; SIRT1; SIRT2; SIRTUINS;

ACETYLATION; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; NEOPLASM PROTEINS; SIRTUIN 2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894490851     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.487736     Document Type: Article

References (49)

1. Frye, R. A. (1999) Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 260, 273-279
2. Frye, R. A. (2000) Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273, 793-798
3. Imai, S., Armstrong, C. M., Kaeberlein, M., and Guarente, L. (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795-800
4. Landry, J., Sutton, A., Tafrov, S. T., Heller, R. C., Stebbins, J., Pillus, L., and Sternglanz, R. (2000) The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl. Acad. Sci. U.S.A. 97, 5807-5811
5. Smith, J. S., Brachmann, C. B., Celic, I., Kenna, M. A., Muhammad, S., Starai, V. J., Avalos, J. L., Escalante-Semerena, J. C., Grubmeyer, C., Wolberger, C., and Boeke, J. D. (2000) A phylogenetically conserved NADdependent protein deacetylase activity in the Sir2 protein family. Proc. Natl. Acad. Sci. U.S.A. 97, 6658-6663
6. Milne, J. C., and Denu, J. M. (2008) The Sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol. 12, 11-17
7. Haigis, M. C., and Sinclair, D. A. (2010) Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253-295
8. Longo, V. D., and Kennedy, B. K. (2006) Sirtuins in aging and age-related disease. Cell 126, 257-268
9. Perrod, S., Cockell, M. M., Laroche, T., Renauld, H., Ducrest, A. L., Bonnard, C., and Gasser, S. M. (2001) A cytosolic NAD-dependent deacetylase, Hst2p, can modulate nucleolar and telomeric silencing in yeast. EMBO J. 20, 197-209
10. Zhao, K., Chai, X., and Marmorstein, R. (2003) Structure of the yeast Hst2 protein deacetylase in ternary complex with 2-O-acetyl ADP ribose and histone peptide. Structure 11, 1403-1411
11. Sauve, A. A., Wolberger, C., Schramm, V. L., and Boeke, J. D. (2006) The biochemistry of sirtuins. Annu. Rev. Biochem. 75, 435-465
12. Das, C., Lucia, M. S., Hansen, K. C., and Tyler, J. K. (2009) CBP/p300-mediated acetylation of histone H3 on lysine. Nature 459, 113-117
13. Vaquero, A., Scher, M. B., Lee, D. H., Sutton, A., Cheng, H. L., Alt, F. W., Serrano, L., Sternglanz, R., and Reinberg, D. (2006) SirT2 is a histone deacetylase with preference for histone H4 Lys-16 during mitosis. Genes Dev. 20, 1256-1261
14. Peck, B., Chen, C. Y., Ho, K. K., Di Fruscia, P., Myatt, S. S., Coombes, R. C., Fuchter, M. J., Hsiao, C. D., and Lam, E. W. (2010) SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol. Cancer Ther. 9, 844-855
15. Rothgiesser, K. M., Erener, S., Waibel, S., Lüscher, B., and Hottiger, M. O. (2010) SIRT2 regulates NF-κB-dependent gene expression through deacetylation of p65 Lys-310. J. Cell Sci. 123, 4251-4258
16. Jing, E., Gesta, S., and Kahn, C. R. (2007) SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab. 6, 105-114
17. Wang, F., Nguyen, M., Qin, F. X., and Tong, Q. (2007) SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 6, 505-514
18. North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M., and Verdin, E. (2003) The human Sir2 ortholog, SIRT2, is an NADdependent tubulin deacetylase. Mol. Cell 11, 437-444
19. de Oliveira, R. M., Sarkander, J., Kazantsev, A. G., and Outeiro, T. F. (2012) SIRT2 as a therapeutic target for age-related disorders. Front. Pharmacol. 3, 82
20. North, B. J., and Verdin, E. (2007) Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PloS One 2, e784
21. Dryden, S. C., Nahhas, F. A., Nowak, J. E., Goustin, A. S., and Tainsky, M. A. (2003) Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol. Cell. Biol. 23, 3173-3185
22. Inoue, T., Hiratsuka, M., Osaki, M., and Oshimura, M. (2007) The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 6, 1011-1018
23. Bosch-Presegué, L., and Vaquero, A. (2011) The dual role of sirtuins in cancer. Genes Cancer 2, 648-662
24. Jin, Y. H., Kim, Y. J., Kim, D. W., Baek, K. H., Kang, B. Y., Yeo, C. Y., and Lee, K. Y. (2008) Sirt2 interacts with 14-3-3-/-and down-regulates the activity of p53. Biochem. Biophys. Res. Commun. 368, 690-695
25. Luo, J., Nikolaev, A. Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., and Gu, W. (2001) Negative control of p53 by Sir2 promotes cell survival under stress. Cell 107, 137-148
26. Heltweg, B., Gatbonton, T., Schuler, A. D., Posakony, J., Li, H., Goehle, S., Kollipara, R., Depinho, R. A., Gu, Y., Simon, J. A., and Bedalov, A. (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66, 4368-4377
27. Li, Y., Matsumori, H., Nakayama, Y., Osaki, M., Kojima, H., Kurimasa, A., Ito, H., Mori, S., Katoh, M., Oshimura, M., and Inoue, T. (2011) SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells 16, 34-45
28. Ouaïssi, M., Sielezneff, I., Silvestre, R., Sastre, B., Bernard, J. P., Lafontaine, J. S., Payan, M. J., Dahan, L., Pirrò, N., Seitz, J. F., Mas, E., Lombardo, D., and Ouaissi, A. (2008) High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann. Surg. Oncol. 15, 2318-2328
29. Kim, H. S., Vassilopoulos, A., Wang, R. H., Lahusen, T., Xiao, Z., Xu, X., Li, C., Veenstra, T. D., Li, B., Yu, H., Ji, J., Wang, X. W., Park, S. H., Cha, Y. I., Gius, D., and Deng, C. X. (2011) SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20, 487-499
30. Luthi-Carter, R., Taylor, D. M., Pallos, J., Lambert, E., Amore, A., Parker, A., Moffitt, H., Smith, D. L., Runne, H., Gokce, O., Kuhn, A., Xiang, Z., Maxwell, M. M., Reeves, S. A., Bates, G. P., Neri, C., Thompson, L. M., Marsh, J. L., and Kazantsev, A. G. (2010) SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 107, 7927-7932
31. Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufareva, I., Strathearn, K. E., Amore, A. M., Volk, C. B., Maxwell, M. M., Rochet, J. C., McLean, P. J., Young, A. B., Abagyan, R., Feany, M. B., Hyman, B. T., and Kazantsev, A. G. (2007) Sirtuin 2 inhibitors rescue synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519
32. Pallos, J., Bodai, L., Lukacsovich, T., Purcell, J. M., Steffan, J. S., Thompson, L. M., and Marsh, J. L. (2008) Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17, 3767-3775
33. Littlewood, T. D., Hancock, D. C., Danielian, P. S., Parker, M. G., and Evan, G. I. (1995) A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23, 1686-1690
34. Schuler, M., Maurer, U., Goldstein, J. C., Breitenbücher, F., Hoffarth, S., Waterhouse, N. J., and Green, D. R. (2003) p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ. 10, 451-460
35. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139, 271-279
36. Beher, D., Wu, J., Cumine, S., Kim, K. W., Lu, S. C., Atangan, L., and Wang, M. (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74, 619-624
37. Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E. A., Caldwell, S. D., Napper, A., Curtis, R., DiStefano, P. S., Fields, S., Bedalov, A., and Kennedy, B. K. (2005) Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280, 17038-17045
38. Pan, M., Yuan, H., Brent, M., Ding, E. C., and Marmorstein, R. (2012) SIRT1 contains N-and C-terminal regions that potentiate deacetylase activity. J. Biol. Chem. 287, 2468-2476
39. Fraga, M. F., and Esteller, M. (2007) Epigenetics and aging: the targets and the marks. Trends Genet. 23, 413-418
40. Meiler, J., Guyot, M., Hoffarth, S., Wesarg, E., Höhn, Y., Breitenbuecher, F., and Schuler, M. (2012) Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 138, 1385-1394
41. Vater, C. A., Bartle, L. M., Dionne, C. A., Littlewood, T. D., and Goldmacher, V. S. (1996) Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53-/-mouse embryo fibroblasts. Oncogene 13, 739-748
42. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825
43. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., and Tanaka, N. (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053-1058
44. Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., and Vogelstein, B. (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7, 673-682
45. Zhang, Y., Au, Q., Zhang, M., Barber, J. R., Ng, S. C., and Zhang, B. (2009) Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem. Biophys. Res. Commun. 386, 729-733
46. Gu, W., and Roeder, R. G. (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606
47. New, M., Olzscha, H., and La Thangue, N. B. (2012) HDAC inhibitorbased therapies: can we interpret the code? Mol. Oncol. 6, 637-656
48. Taylor, D. M., Balabadra, U., Xiang, Z., Woodman, B., Meade, S., Amore, A., Maxwell, M. M., Reeves, S., Bates, G. P., Luthi-Carter, R., Lowden, P. A., and Kazantsev, A. G. (2011) A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem. Biol. 6, 540-546
49. Chopra, V., Quinti, L., Kim, J., Vollor, L., Narayanan, K. L., Edgerly, C., Cipicchio, P. M., Lauver, M. A., Choi, S. H., Silverman, R. B., Ferrante, R. J., Hersch, S., and Kazantsev, A. G. (2012) The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2, 1492-1497